Literature DB >> 6153563

Infusional 5-fluorouracil and X-ray therapy for non-resectable esophageal cancer.

J E Byfield, R Barone, J Mendelsohn, S Frankel, L Quinol, T Sharp, S Seagren.   

Abstract

Six patients with unresectable carcinoma of the esophagus received a combined course of external radiation therapy (1000 rads in four fractions in four days commencing on day 2) combined with constant infusional 5-fluorouracil (20 mg/kg every 24 hours for five days beginning on day 1). This program was repeated every other week to give a total x-ray dose of 6000 rads. This regimen has been well-tolerated by the majority of the patients and resulted in a complete response rate within the x-ray treatment field of 83% (5/6). All patients who showed a demonstrable systemic response to 5-fluorouracil reached complete response. The median survival has not yet been reached at six months with post-treatment survivors alive and without disease (four patients) at one, six, nine, and 22 months. Our previous median survival by x-ray therapy alone was 4 1/2 months. Toxicity consists primarily of hematologic suppression at a subclinical level. Although the length of therapy is substantial (11 weeks), the program appears tolerable and is capable of inducing long-term remissions. The program is currently being studied for dose escalation because neither local nor systemic side effects of a dose-limiting nature have been observed at 20 mg/kg 5-FU.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6153563     DOI: 10.1002/1097-0142(19800215)45:4<703::aid-cncr2820450415>3.0.co;2-q

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Management of anal epidermoid carcinoma--an evaluation of treatment results in two population-based series.

Authors:  S Goldman; B Glimelius; U Glas; G Lundell; L Påhlman; E Ståhle
Journal:  Int J Colorectal Dis       Date:  1989-12       Impact factor: 2.571

2.  Radio(chemo)therapy for locally advanced squamous cell carcinoma of the esophagus: long-term outcome.

Authors:  Arif Deniz Ordu; Carsten Nieder; Hans Geinitz; Philipp Günther Kup; Lisa Felicia Deymann; Vera Scherer; Stephanie E Combs; Khashayar Fakhrian
Journal:  Strahlenther Onkol       Date:  2014-11-18       Impact factor: 3.621

3.  Increased resectability of locally advanced pancreatic and periampullary carcinoma with neoadjuvant chemoradiotherapy.

Authors:  J L Weese; M L Nussbaum; A R Paul; P F Engstrom; L J Solin; M J Kowalyshyn; J P Hoffman
Journal:  Int J Pancreatol       Date:  1990 Aug-Nov

Review 4.  Combined modality therapy for esophageal cancer.

Authors:  Z Gamliel; M J Krasna
Journal:  Curr Oncol Rep       Date:  1999       Impact factor: 5.075

Review 5.  Cancer of the esophagus: the Wayne State University experience.

Authors:  L Leichman
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

6.  [Chemotherapy of esophageal and cardial carcinomas].

Authors:  G A Nagel; A Scherpe
Journal:  Langenbecks Arch Chir       Date:  1981

7.  Update in cancer chemotherapy: gastrointestinal cancer--colorectal cancer, Part 2.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1986-05       Impact factor: 1.798

8.  Addition of Induction or Consolidation Chemotherapy in Definitive Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone for Patients With Unresectable Esophageal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Jianing Wang; Linlin Xiao; Shuai Wang; Qingsong Pang; Jun Wang
Journal:  Front Oncol       Date:  2021-09-13       Impact factor: 6.244

9.  A randomized study to compare sequential chemoradiotherapy with concurrent chemoradiotherapy for unresectable locally advanced esophageal cancer.

Authors:  Arunima Gupta; Somnath Roy; Anup Majumdar; Avijit Hazra; Chandrani Mallik
Journal:  Indian J Med Paediatr Oncol       Date:  2014-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.